.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,929,028

« Back to Dashboard
Patent 5,929,028 protects FOLLISTIM AQ and is included in two NDAs.

This patent has thirty-five patent family members in twenty-six countries.

Summary for Patent: 5,929,028

Title: Liquid gonadotropin containing formulations
Abstract:The invention concerns a liquid gonadotropin-containing formulation characterised in that the formulation comprises a gonadotropin and stabilising amounts of a polycarboxylic acid or a salt thereof and of a thioether compound. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with the particular stabilizers in an aqueous solution. The preparations contain a sufficient amount of the polycarboxylic acid or a salt thereof, preferably sodium citrate, and a sufficient amount of the thioether compound, preferably methionine, to stabilize the protein. The preparations preferably also include a nonreducing disaccharide like sucrose, and a non-ionic surfactant.
Inventor(s): Skrabanja; Arnold Titus Philip (An Nijmegen, NL), van den Oetelaar; Petrus Johannes Maria (Et Heesch, NL)
Assignee: Akzo Nobel, N.V. (Arnhem, NL)
Application Number:09/006,812
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 15th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Organon Usa Inc
FOLLISTIM AQ
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021211-003Feb 11, 2004DISCNNo5,929,028► subscribeY TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
Organon Usa Inc
FOLLISTIM AQ
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021211-003Feb 11, 2004DISCNNo5,929,028► subscribeY METHOD OF TREATING INFERTILITY
Organon Usa Inc
FOLLISTIM AQ
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021211-001Mar 23, 2004RXYes5,929,028► subscribeY TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,929,028

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Netherlands97200099Jan 15, 1997

International Patent Family for Patent: 5,929,028

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina011410► subscribe
Austria237348► subscribe
Australia5205998► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc